Copyright
©The Author(s) 2020.
World J Gastrointest Endosc. Nov 16, 2020; 12(11): 408-450
Published online Nov 16, 2020. doi: 10.4253/wjge.v12.i11.408
Published online Nov 16, 2020. doi: 10.4253/wjge.v12.i11.408
Table 49 Diagnostic endoscopy and colonoscopy with biopsy
| Ref. | Year | Country | Study design | n | Procedure | Medication | Relative risk |
| Fujita et al[5] | 2015 | Japan | Retrospective | 5 (7939) | Endoscopic biopsy | DOAC (continued) | No incidence of PPB |
| Ara et al[6] | 2015 | Japan | Prospective | 394 (3758) | Endoscopic biopsy | DOAC either: (1) Continued; (2) Ceased before | No incidence of PPB(in both continuous and DOAC cessation group) |
| Yuki et al[7] | 2017 | Japan | Prospective | 45 (549) | Endoscopic biopsy | DOAC (continued) | No incidence of PPB |
| Kono et al[105] | 2017 | Japan | Prospective | 51 (221) | Endoscopic biopsy | DOAC (continued) | No incidence of PPB |
- Citation: Chan A, Philpott H, Lim AH, Au M, Tee D, Harding D, Chinnaratha MA, George B, Singh R. Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence. World J Gastrointest Endosc 2020; 12(11): 408-450
- URL: https://www.wjgnet.com/1948-5190/full/v12/i11/408.htm
- DOI: https://dx.doi.org/10.4253/wjge.v12.i11.408